Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05FTJ
|
||||
| Former ID |
DAP000779
|
||||
| Drug Name |
Mefenamic acid
|
||||
| Synonyms |
ApoMefenamic; Bonabol; Contraflam; Coslan; Dysman; Lysalgo; Mefac; Mefacit; Mefedolo; Mefenacid;Mefenamate; Mefenaminsaeure; Mefic; Mycasaal; Namphen; NuMefenamic; Parkemed; Pinalgesic; Ponalar; Ponalgic; Ponmel; Ponstan; Ponstel; Ponstil; Ponstyl; Ponsyl; Pontal; Rolan; Tanston; Vialidon; APS Brand of Mefenamic Acid; Acide mefenamique; Acide mefenamique [French]; Acido mefenamico; Acidum mefenamicum; Antigen Brand of Mefenamic Acid; Apo Mefenamic; Apotex Brand of Mefenamic Acid; Ashbourne Brand of Mefenamic Acid; Chemidex Brand of Mefenamic Acid; Clonmel Brand of Mefenamic Acid; Elan Brand of Mefenamic Acid; Farmasierra Brand of Mefenamic Acid; First Horizon Brand of Mefenamic Acid; Godecke Brand of Mefenamic Acid; Mefanamic acid; Mefenaminic Acid; Mefenaminsaeure [German]; Mephenamic acid; Mephenaminic acid; Methenamic acid; Nu Mefenamic; Nu Pharm Brand of Mefenamic Acid; PMS Mefenamic Acid; Parke Davis Brand of Mefenamic Acid; Pfizer Brand of Mefenamic Acid; Pharmascience Brand of Mefenamic Acid; Pinewood Brand of Mefenamic Acid; Ponstan forte; Rowa Brand of Mefenamic Acid; Tamany Bonsan; Warner Lambert Brand of Mefenamic Acid; CL 473; CN 35355; HL 1; ID8; INF 3355; M1782; AGN-1255; Ac. mefenamico; Ac. mefenamico [Italian]; Acid, Mefenamic; Acid, Mefenaminic; Acide mefenamique [INN-French]; Acido mefenamico [INN-Spanish]; Acidum mefenamicum [INN-Latin]; Apo-Mefenamic; Bafameritin-M; Bafhameritin-M; CN-35355; Dyfenamic (TN); F0850-6853; Forte, Ponstan; INF-3355; In-M; Mafepain (TN); Meftal (TN); Mephadolor (TN); Nu-Mefenamic; Nu-Pharm Brand of Mefenamic Acid; PMS-Mefenamic Acid; Parkemed (TN); Ponstal (TN); Ponstan (TN); Ponstel (TN); Potarlon (TN); Warner-Lambert Brand of Mefenamic Acid; Mefenamic acid (JP15/USP/INN); Mefenamic acid [USAN:INN:BAN:JAN]; N-2,3-Xylylanthranilic acid; N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; 2-(2,3-Dimethylanilino)benzoic acid; 2-(2,3-Xylidino)benzoic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; 2-[(2,3-dimethylphenyl)amino]benzoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatold arthritis; Osteoarthritis; Dysmenorrhea [ICD9: 714, 715, 625.3; ICD10:M05-M06, M15-M19, M47, N94.4-N94.6] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antiinflammatory Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H15NO2
|
||||
| InChI |
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
|
||||
| InChIKey |
HYYBABOKPJLUIN-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 61-68-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5243, 399652, 798379, 840129, 855723, 4906250, 7847219, 7872085, 7979881, 8149703, 8152534, 10321491, 10530006, 11112163, 11335473, 11360712, 11363068, 11365630, 11368192, 11372043, 11374868, 11376354, 11461684, 11466082, 11467202, 11485737, 11485864, 11489757, 11490897, 11493049, 11493988, 14847469, 24424559, 24715034, 24896815, 26512268, 26612162, 26679725, 26746974, 26746975, 26751493, 29223155, 46505405, 47365092, 47440151, 47440152, 47662184, 47662185, 48035004, 48184900
|
||||
| SuperDrug ATC ID |
M01AG01
|
||||
| SuperDrug CAS ID |
cas=000061687
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [4] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | |||||
| C20 prostanoid biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TSH Signaling Pathway | |||||
| IL4 Signaling Pathway | |||||
| TGF_beta_Receptor Signaling Pathway | |||||
| IL5 Signaling Pathway | |||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Inflammation mediated by chemokine and cytokine signaling pathway | |||||
| Toll receptor signaling pathway | |||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
| S1P1 pathway | |||||
| C-MYB transcription factor network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Aryl Hydrocarbon Receptor | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 015034. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2593). | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 4 | Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.